KalVista Pharmaceuticals (KALV) Current Leases (2017 - 2025)

KalVista Pharmaceuticals (KALV) has 9 years of Current Leases data on file, last reported at $2.1 million in Q3 2025.

• For the quarter ending Q3 2025, Current Leases rose 67.88% year-over-year to $2.1 million; the trailing twelve-month figure through Jul 2025 stood at $2.1 million (up 67.88% YoY), and the FY2025 full-year result was $2.0 million, up 51.84% from the prior year.
• Current Leases grew to $2.1 million in Q3 2025, from $2.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.1 million in Q3 2025 to a low of $592000.0 in Q1 2021.
• A 5-year average of $1.2 million and a median of $1.1 million in 2023 frame the typical range for Current Leases.
• Peak annual rise in Current Leases reached 120.38% in 2021, while the deepest fall reached 0.0% in 2021.
• Tracing KALV's Current Leases over 5 years: stood at $930000.0 in 2021, then increased by 10.32% to $1.0 million in 2022, then climbed by 11.89% to $1.1 million in 2023, then grew by 26.48% to $1.5 million in 2024, then jumped by 46.14% to $2.1 million in 2025.
• Business Quant data shows KALV's Current Leases at $2.1 million in Q3 2025, $2.0 million in Q2 2025, and $1.5 million in Q4 2024.